Changing epidemiology of calcific aortic valve disease: 30-year trends of incidence, prevalence, and deaths across 204 countries and territories
- PMID: 33973531
- PMCID: PMC8148466
- DOI: 10.18632/aging.202942
Changing epidemiology of calcific aortic valve disease: 30-year trends of incidence, prevalence, and deaths across 204 countries and territories
Abstract
Calcific aortic valve disease (CAVD) is associated with increased morbidity and mortality. We aimed to elucidate the 30-year epidemiology of CAVD globally. Global CAVD incidence, prevalence, and deaths increased 3.51-, 4.43-, and 1.38-fold from 1990 to 2019, respectively, without any decreasing trends, even after age standardization. In 2019, Slovenia had the highest age-standardized rate (ASR) of CAVD incidence (62.21/100,000 persons) and prevalence (1,080.06/100,000) whereas Cyprus had the highest ASR of deaths (8.20/100,000). Population aging was an important contributor to incidence. Compared with women, more men had CAVD and men had earlier peaks in disease prevalence. High systolic blood pressure, diet high in sodium, and lead exposure were the main risk factors for deaths owing to CAVD. The estimated annual percentage change, a measure to estimate the variation of ASR, was significantly associated with the ASR and sociodemographic index (SDI) in 2019 for incidence and prevalence across all 204 countries and territories (all p<0.0001). With increased lifespan and risk factors, the overall burden of CAVD is high and remains on the rise, with differences by sex, age, and SDI level. Our findings serve to sound the alarm for organizations, institutions, and resources whose primary purpose is to improve human health.
Keywords: 30-year trends; calcific aortic valve disease; epidemiology; incidence; prevalence.
Conflict of interest statement
Figures







Similar articles
-
Global, Regional, and National Burden of Calcific Aortic Valve and Degenerative Mitral Valve Diseases, 1990-2017.Circulation. 2020 May 26;141(21):1670-1680. doi: 10.1161/CIRCULATIONAHA.119.043391. Epub 2020 Mar 29. Circulation. 2020. PMID: 32223336
-
Alerting trends in epidemiology for calcific aortic valve disease, 1990-2019: An age-period-cohort analysis for the Global Burden of Disease Study 2019.Eur Heart J Qual Care Clin Outcomes. 2023 Aug 7;9(5):459-473. doi: 10.1093/ehjqcco/qcad018. Eur Heart J Qual Care Clin Outcomes. 2023. PMID: 36893802 Free PMC article.
-
[Sex and age distribution of global disease burden of calcific aortic valve disease].Zhejiang Da Xue Xue Bao Yi Xue Ban. 2025 Jan 25;54(1):21-27. doi: 10.3724/zdxbyxb-2024-0610. Zhejiang Da Xue Xue Bao Yi Xue Ban. 2025. PMID: 39828273 Free PMC article. Chinese.
-
Calcific aortic valve disease: is it another face of atherosclerosis?Indian Heart J. 2015 Sep-Oct;67(5):503-6. doi: 10.1016/j.ihj.2015.07.033. Epub 2015 Aug 21. Indian Heart J. 2015. PMID: 26432749 Free PMC article. Review.
-
Sex-Specific Features of Calcific Aortic Valve Disease.Int J Mol Sci. 2020 Aug 6;21(16):5620. doi: 10.3390/ijms21165620. Int J Mol Sci. 2020. PMID: 32781508 Free PMC article. Review.
Cited by
-
Genetic proxy of lipid-lowering drugs and calcific aortic valve stenosis: A Mendelian randomization study.Heliyon. 2024 Jul 3;10(13):e34089. doi: 10.1016/j.heliyon.2024.e34089. eCollection 2024 Jul 15. Heliyon. 2024. PMID: 39055828 Free PMC article.
-
Global, regional, and national time trends in disability-adjusted life years, mortality, and variable risk factors of non-rheumatic calcified aortic valve disease, 1990-2019: an age-period-cohort analysis of the Global Burden of Disease 2019 study.J Thorac Dis. 2023 Apr 28;15(4):2079-2097. doi: 10.21037/jtd-23-480. Epub 2023 Apr 25. J Thorac Dis. 2023. PMID: 37197484 Free PMC article.
-
Perceval valve intermediate outcomes: a systematic review and meta-analysis at 5-year follow-up.J Cardiothorac Surg. 2023 Apr 11;18(1):129. doi: 10.1186/s13019-023-02273-7. J Cardiothorac Surg. 2023. PMID: 37041628 Free PMC article.
-
Global, regional, and national burden of non-rheumatic valvular heart disease and Its projections to 2035: comprehensive analysis of the global burden of disease study 2019.Front Cardiovasc Med. 2025 Aug 1;12:1445024. doi: 10.3389/fcvm.2025.1445024. eCollection 2025. Front Cardiovasc Med. 2025. PMID: 40822005 Free PMC article.
-
Integrated proteomic and metabolomic profile analyses of cardiac valves revealed molecular mechanisms and targets in calcific aortic valve disease.Front Cardiovasc Med. 2022 Oct 13;9:944521. doi: 10.3389/fcvm.2022.944521. eCollection 2022. Front Cardiovasc Med. 2022. PMID: 36312243 Free PMC article.
References
-
- Rajamannan NM, Evans FJ, Aikawa E, Grande-Allen KJ, Demer LL, Heistad DD, Simmons CA, Masters KS, Mathieu P, O’Brien KD, Schoen FJ, Towler DA, Yoganathan AP, Otto CM. Calcific aortic valve disease: not simply a degenerative process: A review and agenda for research from the National Heart and Lung and Blood Institute Aortic Stenosis Working Group. Executive summary: Calcific aortic valve disease-2011 update. Circulation. 2011; 124:1783–91. 10.1161/CIRCULATIONAHA.110.006767 - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
Supplementary concepts
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical